New Delhi, Sept. 26 -- European countries are expected to face the most immediate and severe impact from the new U.S. tariffs on imported branded or patented pharmaceutical products, while India may remain less affected for now, according to a press release by the Global Trade Research Initiative (GTRI).

On Friday, U.S. President Donald Trump announced that from October 1, a 100 per cent tariff would be imposed on all imported branded or patented pharmaceutical products, unless the manufacturer is already building a drug-making facility in the U.S. The decision is part of the administration's "America First Manufacturing" push, aimed at forcing global companies to localise production.

"U.S. import data for 2024 shows total pharmaceutica...